

Table 2. Complications by laparoscopic Red-Cross hospital (from July, 1999 to 1

	Laparoscopy (n = 107)
Bile duct damage	0 (0%)
Liver abscess	1 (0.9%)
Inter-costal arterial injury	0 (0%)
Hemothorax	0 (0%)
Hepatic infarction	0 (0%)
Hepatic dysfunction	0 (0%)
Skin burn	0 (0%)
Subcutaneous hematoma	1 (0.9%)
Peumothorax	0 (0%)
Gastrointestinal perforation	0 (0)
Total	2 (1.8%)

Conclusion

RFA is promising for improving patient survival with early stage of HCC when performed skillfully to avoid serious complication. To prevent the recurrence of HCC is the most important issue for achieving better survival.

References

1

Lin SM, Lin CC, Chen WT, Chen YC, Hsu CW. Radiofrequency ablation for hepatocellular carcinoma: a prospective comparison of four radiofrequency devices. *J. Vasc. Interv. Radiol.* 2007; **18**: 1118–25.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 5](#)

2

Tateishi R, Shiina S, Teratani T et al. Percutaneous radiofrequency ablation for

hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005; 103: 1201–9.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(119K\)](#)
- [References](#)

3

Yan K, Chen MH, Yang W et al. Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur. J. Radiol. 2008; 67: 334–47.

[CrossRef](#), [Web of Science® Times Cited: 10](#)

4

Teratani T, Yoshida H, Shiina S et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 2006; 43: 1101–8.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(1051K\)](#)
- [References](#)

5

Song I, Rhim H, Lim HK, Kim YS, Choi D. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tract with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur. Radiol. 2009; 19: 2630–40.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 2](#)

6

De Baere T, Rehim MA, Teriitheau C et al. Usefulness of guiding needles for radiofrequency ablative treatment of liver tumors. Cardiovasc. Intervent. Radiol. 2006; 29: 650–4.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 8](#)

7

Hirooka M, Kisaka Y, Uehara T et al. Efficacy of laparoscopic radiofrequency ablation for hepatocellular carcinoma to percutaneous radiofrequency ablation with artificial ascites. Dig. Endosc. 2009; 21: 82–6.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(262K\)](#)
- [References](#)

8

Asahina Y, Nakanishi Y, Izumi N. Laparoscopic radiofrequency ablation for hepatocellular

carcinoma. Dig. Endosc. 2009; 21: 67–72.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(338K\)](#)
- [References](#)

9

Norimiya T, Seo Y, Yano Y et al. Evaluation of the therapeutic effects using MD-CT immediately after RFA for HCC. Hepatogastroenterology 2006; 53: 558–60.

[PubMed](#), [Web of Science®](#)

10

Gallotti A, D'Onofrio M, Ruzzenente A et al. Contrast-enhanced ultrasonography (CEUS) immediately after percutaneous ablation of hepatocellular carcinoma. Radiol. Med. 2009; 114: 1094–105.

[CrossRef](#), [PubMed](#), [CAS](#), [Web of Science®](#) Times Cited: 1

11

Kisaka Y, Hirooka M, Koizumi Y et al. Contrast-enhanced sonography with abdominal virtual sonography in monitoring radiofrequency ablation of hepatocellular carcinoma. J. Clin. Ultrasound 2010; 38: 138–44.

[PubMed](#)

12

N'Kontchou G, Mahamoudi A, Aout M et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009; 50: 1475–83.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(341K\)](#)
- [References](#)

13

Livraghi T, Meloni F, Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008; 47: 82–9.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(236K\)](#)
- [References](#)

14

Peng ZW, Zhang YJ, Chen MS, Liang HH, Li JQ, Lau WY. Risk factors of survival after

- percutaneous radiofrequency ablation of hepatocellular carcinoma. Surg. Oncol. 2008; 17: 23–31.*
[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 1](#)
- 15
Choi D, Lim HK, Rhim H et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur. Radiol. 2007; 17: 684–92.
[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 66](#)
- 16
Kobayashi M, Ikeda K, Kawamura Y et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009; 115: 571–80.
Direct Link:
 - [Abstract](#)
 - [Full Article \(HTML\)](#)
 - [PDF\(205K\)](#)
 - [References](#)
- 17
Takahashi S, Kudo M, Chung H et al. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy. Oncology 2008; 75S: 91–8.
[CrossRef](#), [CAS](#)
- 18
Ogawa C, Kudo M, Minami Y, Chung H, Kawasaki T. Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma. Hepatogastroenterology 2008; 55: 1454–7.
[PubMed](#)
- 19
Du XL, Ma QJ, Wu T, Baqo GQ, Lu JG, Chu YK. Significance of alpha-fetoprotein mRNA level in hepatocellular carcinoma patients treated with radiofrequency ablation. Hepatobiliary Pancreat. Dis. Int. 2007; 6: 172–5.
[PubMed](#), [CAS](#), [Web of Science®](#)
- 20
Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann. Surg. Oncol. 2007; 14: 1835–45.
[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 23](#)
- 21
Grieco A, Pompili M, Camitiniti G et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy:

comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; **54**: 411–8.

[CrossRef](#), [PubMed](#), [CAS](#), [Web of Science®](#) Times Cited: 57

22

Yamagiwa K, Shiraki K, Yamamoto K et al. Survival rates according to the cancer of the Italian program score of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study. J. Gastroenterol. Hepatol. 2008; **23**: 482–90.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(263K\)](#)
- [References](#)

23

Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J. Gastroenterol. 2003; **38**: 207–15.

[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 149

24

Kudo M, Chung H, Haji S et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; **40**: 1396–405.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(410K\)](#)
- [References](#)

25

Lee JH, Han SY, Jo JH et al. Prognostic factors for survival in patients with hepatocellular carcinoma after radiofrequency ablation. Korean J. Gastroenterol. 2007; **49**: 17–23.

[PubMed](#)

26

Takahashi S, Kudo M, Chung H et al. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007; **72S**: 98–103.

[CrossRef](#), [Web of Science®](#) Times Cited: 11

27

Liu CH, Arellano RS, Upport RN, Samir AE, Gervais DA, Mueller PR. Radiofrequency ablation of hepatic tumours: effect of post-ablation margin on local tumour progression. Eur. Radiol. 2010; **20**: 877–85.

[CrossRef](#), [PubMed](#), [Web of Science®](#)

28

Lam VW, Ng KK, Chok KS et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. *J. Am. Coll. Surg.* 2008; **207**: 20–9.

[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 14

29

Lam VW, Ng KK, Chok KS et al. Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors. *Ann. Surg. Oncol.* 2008; **15**: 782–90.

[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 7

30

Pitton MB, Herber S, Raab P et al. Percutaneous radiofrequency ablation of liver tumors using the LeVeen 4 cm array probe. *Rofo* 2003; **175**: 1525–31.

[PubMed](#), [CAS](#), [Web of Science®](#) Times Cited: 5

31

Okuwaki Y, Nakazawa T, Shibuya A et al. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. *J. Gastroenterol.* 2008; **43**: 71–8.

[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 5

32

Izumi N, Asahina Y, Noguchi O et al. Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. *Cancer* 2001; **91**: 949–56.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(172K\)](#)
- [References](#)

33

Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. *J. Gastrointest. Surg.* 2009; **12**: 183–91.

[CrossRef](#), [Web of Science®](#) Times Cited: 21

34

Izumi N, Asahina Y, Tsuchiya K et al. Repeated radiofrequency ablation for the distant recurrence in the liver in patients with chronic hepatitis C virus infection achieving long-term survival. *Hepatol. Res.* 2007; **37S2**: S254–63.

Direct Link:

- [Abstract](#)

- [Full Article \(HTML\)](#)
- [PDF\(736K\)](#)
- [References](#)

35

Yamashiki N, Yoshida H, Tateishi R et al. Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment. J. Gastroenterol. Hepatol. 2007; 22: 2155–60.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(118K\)](#)
- [References](#)

36

Kim SH, Lim HK, Choi D et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma: effect of histologic grade on therapeutic results. Am. J. Roentgenol. 2006; 186: S327–33.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 7](#)

37

Kudo M, Sakaguchi Y, Chung H et al. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 2007; 72S: 132–8.

[CrossRef](#), [CAS](#), [Web of Science® Times Cited: 10](#)

38

Kuzuya T, Katano Y, Kumada T et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2007; 22: 1929–35.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(153K\)](#)
- [References](#)

39

Yoshida H, Yoshida H, Goto E et al. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol. Int. 2008; 2: 89–94.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 1](#)

40

Kakizaki S, Sohara N, Sato K et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J. Gastroenterol. Hepatol. 2007; 22: 518–22.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(120K\)](#)
- [References](#)

41

Ishikawa T, Michitaka I, Kamimura H et al. Oral branched-chain amino acids administration improves impaired liver dysfunction after radiofrequency ablation therapy for hepatocellular carcinoma. Hepatogastroenterology 2009; 56: 1491–5.

[PubMed](#), [CAS](#)

42

Lu MD, Kuang M, Liang LJ et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial. Zhonghua Yi Xue Za Zhi 2006; 28: 801–5.

43

Chen MS, Li JQ, Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann. Surg. 2006; 243: 321–8.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 186](#)

44

Guglielmi A, Ruzzenente A, Valdegamberi A et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J. Gastrointest. Surg. 2008; 12: 192–8.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 20](#)

45

Hong SN, Lee SY, Choi MS et al. Comparing the outcomes of radiofrequency ablation and surgery in patients with a single small hepatocellular carcinoma and well-preserved hepatic function. J. Clin. Gastroenterol. 2005; 39: 247–52.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 60](#)

46

Santambrogio R, Opocher E, Zuin M et al. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and child-pugh class A liver cirrhosis. Ann. Surg. Oncol. 2009; 16: 3289–98.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 3](#)

47

Montorsi M, Santambrogio R, Bianchi P et al. Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. J. Gastrointest. Surg. 2005; 9: 62–7.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 35](#)

48

- Abu-Hilal M, Primrose JN, Casaril A, McPhail MJ, Pearce NW, Nicoli N. *Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J. Gastroenterol. Surg.* 2008; **12**: 1521–6.
[CrossRef](#), [PubMed](#), [CAS](#), [Web of Science®](#) Times Cited: 9
- 49
Molinari M, Helton S. *Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. Am. J. Surg.* 2009; **198**: 396–406.
[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 6
- 50
Vivarelli M, Guglielmi A, Ruzzenente A et al. *Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann. Surg.* 2004; **240**: 102–7.
[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 78
- 51
Ohmoto K, Yoshioka N, Tomiyama Y et al. *Radiofrequency ablation versus percutaneous microwave coagulation therapy for small hepatocellular carcinomas: a retrospective comparative study. Hepatogastroenteology* 2007; **54**: 985–9.
[PubMed](#), [Web of Science®](#) Times Cited: 12
- 52
Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. *Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤ 4 cm. Gastroenterology* 2004; **127**: 1714–23.
[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 206
- 53
Shiina S, Teratani T, Obi S et al. *A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology* 2005; **129**: 122–30.
[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 234
- 54
Iwata K, Sohda T, Nishizawa S et al. *Postoperative recurrence in hepatocellular carcinoma: comparison between percutaneous ethanol injection and radiofrequency ablation. Hepatol. Res.* 2006; **36**: 143–8.
[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 2
- 55
Brunello F, Veltri A, Carucci P et al. *Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand. J. Gastroenterol.* 2008; **43**: 727–35.
[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 29
- 56

Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systemic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. *Hepatology* 2009; **49**: 453–9.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(210K\)](#)
- [References](#)

57

Bouza C, Lopez-Cuadrado T, Alcazar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. *BMC Gastroenterol.* 2009; **9**: 31.

[CrossRef](#), [PubMed](#), [CAS](#), [Web of Science® Times Cited: 12](#)

58

Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. Percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. *Am. J. Gastroenterol.* 2009; **104**: 514–24.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 22](#)

59

Zhang YJ, Liang HH, Chen MS et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. *Radiology* 2007; **244**: 599–607.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 22](#)

60

Kirikoshi H, Saito S, Yoneda M et al. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. *Hepatol. Res.* 2009; **39**: 553–62.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(198K\)](#)
- [References](#)

61

Peng ZW, Chen MS, Liang HH et al. A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. *Eur. J. Surg. Oncol.* 2010; **36**: 257–63.

[PubMed](#)

62

Gadaleta C, Catino A, Ranieri G et al. Single-step therapy-feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic

malignancies. In Vivo 2009; **23**: 813–20.

[PubMed](#), [CAS](#)

63

Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). *Eur. Radiol.* 2006; **16**: 661–9.

[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 47

64

Yamakado K, Nakatsuka A, Takaki H et al. Subphrenic versus nonsubphrenic hepatocellular carcinoma: combined therapy with chemoembolization and radiofrequency ablation. *Am. J. Roentgenol.* 2010; **194**: 530–5.

[CrossRef](#), [Web of Science®](#)

65

Maluccio M, Covey AM, Gandhi R et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. *J. Vasc. Interv. Radiol.* 2005; **16**: 955–61.

[PubMed](#), [Web of Science®](#) Times Cited: 28

66

Yamazaki T, Kimura T, Kurokawa F et al. Percutaneous radiofrequency ablation with cooled electrodes combined with hepatic arterial balloon occlusion in hepatocellular carcinoma. *J. Gastroenterol.* 2005; **40**: 171–8.

[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 16

67

Shiraishi R, Yamasaki T, Saeki I et al. Pilot study of combination therapy with transcatheter arterial infusion chemotherapy using iodized oil and percutaneous radiofrequency ablation during occlusion of hepatic blood flow for hepatocellular carcinoma. *Am. J. Clin. Oncol.* 2008; **31**: 311–6.

[CrossRef](#), [PubMed](#), [CAS](#), [Web of Science®](#) Times Cited: 2

68

Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? *Radiology* 2009; **252**: 905–13.

[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 10

69

Kasugai H, Osaki Y, Oka H, Kudo M, Seki T. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3891 ablations in 2614 patients. *Oncology* 2007; **72** (Suppl. 1): 72–5.

[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 8

70

Kong WT, Zhang WW, Qui YD et al. Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients. *World J. Gastroenterol.* 2009; **15**: 2651–6.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 7](#)

71

Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. *Ann. Surg. Oncol.* 2000; **7**: 593–600.

[PubMed](#), [CAS](#), [Web of Science® Times Cited: 269](#)

72

Rhim H, Yoon KH, Lee JM et al. Major complications after radio-frequency thermal ablation of hepatic tumors: a spectrum of imaging findings. *Radiographics* 2003; **23**: 123–34.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 111](#)

73

De Baere T, Risse O, Kuoch V et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. *Am. J. Roentgenol.* 2003; **181**: 695–700.

74

Choi D, Lim HK, Kim MJ et al. Liver abscess after percutaneous radiofrequency ablation for hepatocellular carcinomas: frequency and risk factors. *Am. J. Roentgenol.* 2005; **184**: 1860–7.

[PubMed](#), [Web of Science® Times Cited: 21](#)

75

Elias D, Pietroantonio D, Gachot B, Menegon P, Hakime A, De Baere T. Liver abscess after radiofrequency ablation of tumors in patients with a biliary tract procedure. *Gastroenterol. Clin. Biol.* 2006; **30**: 823–7.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 8](#)

76

Shibata T, Yamamoto Y, Yamamoto N et al. Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. *J. Vasc. Interv. Radiol.* 2003; **14**: 1535–42.

[PubMed](#), [Web of Science® Times Cited: 24](#)

77

Jensen MC, van Duijnhoven FH, van Hellegerberg R et al. Adverse effects of radiofrequency ablation of liver tumors in the Netherlands. *Br. J. Surg.* 2005; **92**: 1248–54.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(111K\)](#)
- [References](#)

78

Ohnishi T, Yasuda I, Nishigaki Y et al. Intraductal chilled saline perfusion to prevent bile duct injury during percutaneous radiofrequency ablation for hepatocellular carcinoma. *J. Gastroenterol. Hepatol.* 2008; **23**: 410–5.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(315K\)](#)
- [References](#)

79

Goto E, Tateishi R, Shiina S et al. Hemorrhagic complications of percutaneous radiofrequency ablation for liver tumors. *J. Clin. Gastroenterol.* 2010; **44**: 374–80.

[PubMed](#)

80

Poggi G, Riccardi A, Quaretti P et al. Complications of percutaneous radiofrequency thermal ablation of primary and secondary lesions of the liver. *Anticancer Res.* 2007; **27**: 2911–6.

[PubMed](#), [Web of Science® Times Cited: 6](#)

81

Sartori S, Tombesi P, Macario F et al. Subcapsular liver tumors treated with percutaneous radiofrequency ablation: a prospective comparison with nonsubcapsular liver tumors for safety and effectiveness. *Radiology* 2008; **248**: 670–9.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 6](#)

82

Kim YJ, Raman SS, Yu NC, Busutil RW, Tong M, Lu DS. Radiofrequency ablation of hepatocellular carcinoma: can subcapsular tumors be safely ablated? *Am. J. Roentgenol.* 2008; **190**: 1029–34.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 4](#)

83

Yeung YP, Hui J, Yip WC. Delayed colonic perforation after percutaneous radiofrequency ablation of hepatocellular carcinoma. *Surg. Laparosc. Endosc. Percutan. Tech.* 2007; **17**: 342–4.

[CrossRef](#), [PubMed](#), [Web of Science® Times Cited: 1](#)

84

Meloni MF, Goldberg SN, Moser V, Piazza G, Livraghi T. Colonic perforation and abscess following radiofrequency ablation of hepatoma. *Eur. J. Ultrasound* 2002; **15**: 73–6.

[CrossRef](#), [PubMed](#)

85

Chan FS, Ng KK, Poon RT, Yuen J, Tso WK, Fan ST. Duodenopleural fistula formation after percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma. *Asian*

J. Surg. 2007; **30**: 278–82.

[CrossRef](#), [PubMed](#), [Web of Science®](#)

86

Kim YS, Rhim H, Lim HK, Choi D, Lee WJ, Kim SH. Hepatic infarction after radiofrequency ablation of hepatocellular carcinoma with an internally cooled electrode. *J. Vasc. Interv. Radiol.* 2007; **18**: 1126–33.

[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 5

87

Zheng RQ, Kudo M, Inui K et al. Transient portal vein thrombosis caused by radiofrequency ablation for hepatocellular carcinoma. *J. Gastroenterol.* 2003; **38**: 101–3.

[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 2

88

Llovet JM, Vilana R, Bru C et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. *Hepatology* 2001; **33**: 1124–9.

Direct Link:

- [Abstract](#)
- [PDF\(136K\)](#)
- [References](#)

89

Livraghi T, Lazzaroni S, Meloni F, Solbiati L. Risk of tumour seeding after percutaneous radiofrequency ablation for hepatocellular carcinoma. *Br. J. Surg.* 2005; **92**: 856–8.

Direct Link:

- [Abstract](#)
- [Full Article \(HTML\)](#)
- [PDF\(76K\)](#)
- [References](#)

90

Imamura J, Tateishi R, Shiina S et al. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. *Am. J. Gastroenterol.* 2008; **103**: 3057–62.

Direct Link:

91

Giorgia A, Tarantino L, de Stafano G, Coppola C, Ferraioli G. Complications after percutaneous saline-enhanced radiofrequency ablation of liver tumors: 3-year experience with 336 patients at a single center. *Am. J. Roentgenol.* 2005; **184**: 207–11.

92

Latteri F, Sandonato L, Di Marco V et al. Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. *Dig. Liver Dis.* 2008; **40**: 684–9.

[CrossRef](#), [PubMed](#), [CAS](#), [Web of Science®](#) Times Cited: 6

93

Shankar S, van Sonnenberg E, Silverman SG, Tuncali K, Morrison PR. Management of pneumothorax during percutaneous radiofrequency ablation of a lung tumor: technical note. J. Thorac. Imaging 2003; 18: 106–9.

[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 8

94

Rodriguez J, Tellioglu G, Siperstein A, Berber E. Myoglobinuria after laparoscopic radiofrequency ablation of liver tumors. J. Gastrointest. Surg. 2010; 14: 664–7.

[CrossRef](#), [PubMed](#), [Web of Science®](#)

95

Tsui SL, Lee AK, Lui SK, Poon RT, Fan ST. Acute intraoperative hemolysis and hemoglobinuria during radiofrequency ablation of hepatocellular carcinoma. Hepatogastroenterology 2003; 50: 526–9.

[PubMed](#)

96

Seki T, Tamai T, Ikeda K et al. Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur. J. Gastroenterol. Hepatol. 2001; 13: 291–4.

[CrossRef](#), [PubMed](#), [CAS](#), [Web of Science®](#) Times Cited: 29

97

Zavaglia C, Corso R, Rampoldi A et al. Is percutaneous radiofrequency thermal ablation of hepatocellular carcinoma a safe procedure? Eur. J. Gastroenterol. Hepatol. 2008; 20: 196–201.

[CrossRef](#), [PubMed](#), [Web of Science®](#) Times Cited: 7

[Get PDF \(362K\)](#)

More content like this

Find more content:

- [like this article](#)

Find more content written by:

- [Namiki Izumi](#)

Original Article

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B

Akihiro Matsumoto,¹ Eiji Tanaka,¹ Yoshiyuki Suzuki,² Mariko Kobayashi,² Yasuhito Tanaka,⁴ Noboru Shinkai,⁴ Shuhei Hige,⁶ Hiroshi Yatsushashi,⁸ Shinya Nagaoka,⁸ Kazuaki Chayama,⁹ Masataka Tsuge,⁹ Osamu Yokosuka,¹⁰ Fumio Imazeki,¹⁰ Shuhei Nishiguchi,¹¹ Masaki Saito,¹¹ Kei Fujiwara,⁵ Nobuyuki Torii,³ Naoki Hiramatsu,¹² Yoshiyasu Karino⁷ and Hiromitsu Kumada²

¹Department of Medicine, Shinshu University School of Medicine, Matsumoto, ²Department of Hepatology, Toranomon Hospital, ³Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University, Tokyo, ⁴Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, ⁵Gastroenterology Section, Nagoya Daini Red Cross Hospital, Nagoya, ⁶Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, ⁷Department of Gastroenterology, Sapporo Kosei General Hospital, Sapporo, ⁸The Clinical Research Center, NHO Nagasaki Medical Center, Omura, ⁹Program for Biomedical Research, Division of Frontier Medical Science, Department of Medicine and Molecular Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, ¹⁰Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, ¹¹Division of Hepatobiliary and Pancreatic Diseases, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, and ¹²Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan

Aim: The factors associated with hepatitis recurrence after discontinuation of nucleos(t)ide analogs (NAs) in patients with chronic hepatitis B were analyzed to predict the risk of relapse more accurately.

Methods: A total of 126 patients who discontinued NA therapy were recruited retrospectively. The clinical conditions of a successful discontinuation were set as alanine aminotransferase (ALT) below 30 IU/L and serum hepatitis B virus (HBV) DNA below 4.0 log copies/mL.

Results: Relapse of hepatitis B were judged to occur when maximal serum ALT became higher than 79 IU/L or when maximal serum HBV DNA surpassed 5.7 log copies/mL following NA discontinuation since these values corresponded with mean values of ALT (30 IU/L) and HBV DNA (4.0 log copies/mL), respectively. At least 90% of patients with either detectable hepatitis B e antigen or serum HBV DNA higher than 3.0 log

copies/mL at the time of NA discontinuation relapsed within one year. In the remaining patients, higher levels of both hepatitis B surface and core-related antigens at the time of discontinuation, as well as a shorter course of NA treatment, were significantly associated with relapse by multivariate analysis.

Conclusions: It appears that negative results for hepatitis B e antigen and serum HBV DNA lower than 3.0 log copies/mL are essential for successful NA discontinuation, which may be attained by a longer treatment period. Levels of hepatitis B surface and core-related antigens are also significant factors independently associated with relapse of hepatitis.

Key words: discontinuation, hepatitis B core-related antigen, hepatitis B surface antigen, nucleos(t)ide analogs, relapse of hepatitis

Correspondence: Professor Eiji Tanaka, Department of Medicine, Gastroenterology Division, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Email: etanaka@shinshu-u.ac.jp

Financial support

This research was supported in part by a research grant from the Ministry of Health, Labor and Welfare of Japan.

Received 7 August 2011; revision 31 August 2011; accepted 5 September 2011.

INTRODUCTION

HEPATITIS B VIRUS (HBV) infection is a major health concern that has an estimated 350 to 400 million carriers worldwide. Chronic infection with HBV can cause chronic hepatitis, and may eventually develop into liver cirrhosis and hepatocellular carcinoma.¹⁻³ Over the last decade, major advances in the treatment of chronic hepatitis B have been made with nucleos(t)ide

analogs (NAs) such as lamivudine (LVD), adefovir dipivoxil (ADV), and entecavir (ETV).⁴ NAs are orally administered and are associated with low rates of adverse effects. Treatment with NAs shows strong suppression of HBV replication and consequently rapid improvement of elevated ALT levels. Furthermore, these drugs have been reported to lower the risk of complicating cirrhosis and hepatocellular carcinoma,⁵⁻⁷ and so NAs are becoming widely used to treat patients with chronic hepatitis B. On the other hand, NAs carry the risk of developing drug-resistance;⁸ drug-resistant viruses emerging during treatment may be associated with hepatitis flare-ups. Hepatitis B patients are also required to undergo prolonged treatment with NAs because early discontinuance often leads to relapse of hepatitis and ensuing hepatic failure following rises in alanine aminotransferase (ALT) level.^{9,10}

Serum HBV DNA is normally used to monitor the antiviral effect of NAs. HBV DNA decreases rapidly and becomes undetectable in the majority of patients who are treated with NAs,¹¹⁻¹³ but relapse after discontinuation is not rare.¹⁴⁻¹⁷ Since it is also true that favorable virological and biochemical responses to NAs may continue indefinitely in some patients,^{9,15} reliable markers that can predict relapse of hepatitis after NA discontinuation are needed. Such markers would benefit not only patients who are considering discontinuation of NA treatment, but also clinicians, hospitals, and the medical economy.

In the present study, we assessed several factors associated with relapse of hepatitis after discontinuation of NAs in patients with chronic hepatitis B, including hepatitis B viral antigens, which have been reported as new and promising markers for monitoring the effect of antiviral agents, such as interferon and NAs.

METHODS

Patients

A TOTAL OF 126 patients with chronic hepatitis B who underwent and completed NA treatment between 2000 and 2010 were enrolled in this study. Patients were recruited retrospectively from 11 hospitals across Japan (Toranomon Hospital, Hokkaido University Hospital, Nagoya City University Hospital, Shinshu University Hospital, Hiroshima University Hospital, National Hospital Organization Nagasaki Medical Center, Chiba University Hospital, The Hospital of Hyogo College of Medicine, Japanese Red Cross Nagoya Daini Hospital, and Tokyo Women's Medical University Hospital, Sapporo Kosei General Hospital) and met the

following conditions: (i) serum ALT higher than 30 IU/L and serum HBV DNA higher than 4.0 log copies/mL were observed at least twice within the 6 months prior to administration of NAs; (ii) stored serum samples at initiation and discontinuation of NAs were available for measurements of viral markers; (iii) clinical outcomes were followed for at least 6 months after the discontinuation of NAs; and (iv) tests for hepatitis C and human immunodeficiency virus antibodies were negative. Hepatitis B surface antigen (HBsAg) was confirmed to be positive on at least two occasions at least 6 months apart in all patients before treatment. Patients complicated with hepatocellular carcinoma or signs of hepatic failure at treatment discontinuation were excluded from the study. Our cohort consisted of 83 men and 43 women with a median age of 46 (range, 19 to 79) years when NA administration was discontinued. Hepatitis B e antigen (HBeAg) was positive in 64 patients (51%) at the initiation of treatment and in 24 patients (19%) at its discontinuation. HBV genotype was A in two (2%) patients, B in five (4%), C in 102 (81%), and undetermined in 17 (13%). Thirty-five of the 126 patients in this study were younger than 35 years old. Although not recommended as the first line treatment for this group by Japanese guidelines,¹⁸ NA treatment was commenced since chronic active hepatitis had been persisting in all cases irrespective of their HBeAg status (26 positive and nine negative) at the initiation of treatment.

The decision to discontinue NAs was made by individual physicians using similar, but not uniform, conditions. Four patients who halted NAs for financial reasons were included. No patient underwent interferon treatment during or after NA treatment. The decision to recommence NA administration was also made by individual physicians, essentially when relapse of hepatitis became obvious. With few exceptions, patients were seen at least once a month during the first year after discontinuation of NAs, and at least once every several months afterwards. Stored serum samples were kept frozen at -20°C or below until assayed. This study was approved by the Ethics Committees of all participating institutions.

Hepatitis B viral markers

Serological markers for HBV, including HBsAg, HBeAg, and antibody to HBe (anti-HBe) were tested using commercially available enzyme immunoassay kits (Abbott Japan Co., Ltd, Tokyo, Japan; Fujirebio Inc., Tokyo, Japan; and/or Sysmex Co., Kobe, Japan) at each hospital. Quantitative measurement of HBsAg¹⁹ was done using a chemiluminescence enzyme immunoassay

(CLEIA)-based HISCL HBsAg assay manufactured by Sysmex Corporation (Kobe, Japan). The assay had a quantitative range of -1.5 to 3.3 log IU/mL. End titer was determined by diluting samples with normal human serum when initial results exceeded the upper limit of the assay range.

Serum concentration of HBV DNA was determined using an Amplicor HBV monitor kit (Roche, Tokyo, Japan),²⁰ which had a quantitative range of 2.6 to 7.6 log copies/mL. Serum HBV DNA was also determined using a COBAS TaqMan HBV kit (Roche, Tokyo, Japan)²¹ with a quantitative range of 2.1 to 9.0 log copies/mL in 43 patients whose serum samples were available at the time of NA discontinuation. According to the manufacturer's instructions, detection of a positive signal below the quantitative range was described as a positive signal, and no signal detection was described as a negative signal. Six HBV genotypes (A–F) were evaluated according to the restriction patterns of DNA fragments from the method reported by Mizokami *et al.*²²

Serum hepatitis B core-related antigen (HBcrAg) levels were measured using a CLEIA HBcrAg assay kit with a fully automated Lumipulse System analyzer (Fujirebio Inc., Tokyo, Japan) as described previously.^{23,24} Briefly, 150 μ L of serum was incubated with pretreatment solution and then added to a ferrite microparticle suspension in an assay cartridge. Ferrite particles were coated with a monoclonal antibody mixture against denatured HBcAg, HBeAg, and the 22 kDa precore protein. After incubation and washing, further incubation was carried out with alkaline phosphatase conjugated with two kinds of monoclonal antibodies against denatured HBcAg, HBeAg, and the 22 kDa precore protein. Following washing, a substrate solution was added to the test cartridge and then incubated. The relative chemiluminescence intensity was measured, and HBcrAg concentration was calculated by a standard curve generated using recombinant pro-HBeAg. The immunoreactivity of pro-HBeAg at 10 fg/mL was defined as 1 U/mL. We expressed HBcrAg in terms of log U/mL, with a quantitative range set at 3.0 to 6.8 log U/mL.

Statistical analyses

A linear regression model was used to examine for associations between mean and maximal values of both ALT and HBV DNA. Correlations between variables were calculated using the Spearman's rank correlation coefficient test. Each cut-off value was decided using receiver operating characteristic curve (ROC) analysis and results were evaluated by measuring the area under the curve (AUC). The Fisher's exact and Pearson's χ^2 tests

were adopted to test for differences between subgroups of patients. To compare continuous data, the Mann-Whitney *U*-test was used. The Kaplan-Meier method was used to estimate rates of non-relapse observations, and the log-rank test was used to test hypotheses concerning differences in non-relapse observations between selected groups. Multivariate analyses were performed using the Cox regression model. Variables associated with a *P*-value < 0.2 in univariate analyses were included in a stepwise Cox regression analysis to identify independent factors associated with relapse of hepatitis after discontinuation of NAs. All tests were performed using the IBM SPSS Statistics Desktop for Japan ver. 19.0 (IBM Japan Inc., Tokyo, Japan). *P*-values of less than 0.05 were considered to be statistically significant.

RESULTS

Definition of hepatitis relapse after discontinuation of NAs

THE CLINICAL CONDITIONS of a successful discontinuation of NAs were set at serum HBV DNA below 4.0 log copies/mL and ALT below 30 IU/L according to the Japanese guidelines for the treatment of hepatitis B.¹⁸ However, these criteria could not be directly applied to our cohort as post-therapy fluctuations in ALT and HBV DNA were difficult to evaluate consistently. In total, 26 (76%) of 34 patients with successful discontinuation of NAs showed transient abnormal levels of ALT and/or HBV DNA, especially during the early phase after cessation. We therefore used mean and maximal values of these markers to evaluate relapse of hepatitis B in this study; mean values were used to evaluate relapse of hepatitis as a whole, and maximal values were used to dynamically assess relapse during the follow-up period after NA discontinuation. Both ALT and HBV DNA were measured 11.0 times per year on average during the first year and 4.1 times per year on average thereafter.

The mean values of HBV DNA were significantly ($P < 0.001$) correlated with maximal values with a correlation coefficient of 0.853 . Similarly, the mean values of ALT were significantly ($P < 0.001$) correlated with maximal values with a correlation coefficient of 0.940 (Fig. 1). The mean HBV DNA value of 4.0 log copies/mL corresponded to a maximal HBV DNA value of 5.7 by ROC analysis (AUC = 0.930 , $P < 0.001$), and the mean ALT value of 30 IU/L corresponded to a maximal ALT value of 79 IU/L (AUC = 0.988 , $P < 0.001$). These results suggested that patients having serum HBV DNA higher




Figure 1 Correlation between maximal and mean levels of alanine aminotransferase (ALT) (a) and hepatitis B virus (HBV) DNA (b) after discontinuation of nucleos(t)ide analogs (NAs). Open circles indicate patients with detectable hepatitis B e antigen (HBeAg) and closed squares indicate patients without detectable HBeAg.

than 5.7 log copies/mL during the follow-up period after NA discontinuation were not likely to achieve the HBV DNA criterion of a successful discontinuation of below 4.0 log copies/mL. Similarly, it could be inferred that patients reaching ALT levels higher than 79 IU/L would also not likely achieve the ALT criterion of a successful discontinuation of below 30 IU/L.

Based on our findings, we judged that a relapse of hepatitis B occurred when serum ALT exceeded 79 IU/L or when serum HBV DNA exceeded 5.7 log copies/mL

following NA discontinuation. Accordingly, 92 (73%) of the 126 patients enrolled in the present study showed a relapse. We set the follow-up period as discontinuation to relapse for relapse patients and as discontinuation to the last recorded examination for patients without relapse. Whereas re-administration of NAs due to relapse was commenced in 70% of relapse patients in the follow-up period, none was performed in non-relapse patients during that time.

Elimination of cases likely to show relapse of hepatitis

As it is generally believed that patients who are positive for HBeAg and/or have a higher level of HBV DNA at discontinuation of NAs are likely to relapse, these factors were assessed first. The progression of analyses in the present study and the population structure of each analysis are shown in Figure 2.

The non-relapse rate was compared using the Kaplan–Meier method between 31 patients with HBV DNA equal to or higher than 3.0 log copies/mL and 95 patients with levels lower than 3.0 log copies/mL when NAs were discontinued (Fig. 3). The revised cut-off value of 3.0 log copies/mL was determined by ROC analysis (AUC = 0.709, $P < 0.001$). Thirty (97%) of 31 patients with HBV DNA equal to or higher than 3.0 log copies/mL relapsed within one year of discontinuation. On the other hand, approximately 30% of patients with levels lower than 3.0 log copies/mL showed prolonged non-relapse. Thus, the 31 patients with high HBV DNA at the time of discontinuation were eliminated from the following analyses.

In the remaining 95 patients, the non-relapse rate was compared using the Kaplan–Meier method between 10 patients with detectable HBeAg and 85 patients without HBeAg when NAs were discontinued (Fig. 4). Ninety percent of patients with HBeAg experienced relapse within one year, which was significantly ($P = 0.005$) higher than in cases without HBeAg. In patients without HBeAg, the non-relapse rate decreased rapidly during the first year to approximately 45%, and then decreased relatively slowly over the following 3 years to nearly 30%. It is noteworthy that this subgroup did not relapse afterwards. Since the relapse rate was high among patients with detectable HBeAg, they were excluded from the following analyses as well.

Factors associated with relapse of hepatitis after discontinuation of NAs

Additional factors associated with relapse of hepatitis were analyzed in the remaining 85 patients who were




Figure 2 The progression of analyses in the present study and population structure of each analysis.

both negative for HBeAg and whose serum HBV DNA was lower than 3.0 log copies/mL at NA cessation. Table 1 shows the comparison of clinical and virological backgrounds between the 53 relapse and 32 non-relapse patients using univariate analysis. Age and gender distributions were similar between the groups. Approximately 75% of the 85 patients had HBV genotype C, but the distribution of genotypes did not differ between the groups. Approximately 90% of patients were being treated with LVD alone at the time of discontinuation, compared with 6% of patients being given ETV. The median duration of NA treatment was about two times longer in patients without relapse. Levels of both HBsAg

and HBcrAg were significantly lower in non-relapse patients than in relapse patients at the time of NA discontinuation. The difference between serum HBsAg was also significant at the initiation of NAs, but not that of HBcrAg. As only patients with HBV DNA lower than 3.0 log copies/mL were analyzed, the majority of these cases showed levels below the 2.6 log copies/mL lower detection limit of the Amplicor assay at NA discontinuation. We therefore also tested HBV DNA with a TaqMan assay, which had a higher sensitivity than the Amplicor assay, in 43 patients whose serum samples were available. The prevalence of patients having a negative detection signal did not differ between the two groups. The number of




Figure 3 Comparison of non-relapse rates using the Kaplan-Meier method between 31 patients with serum hepatitis B virus (HBV) DNA equal to or higher than 3.0 log copies/mL and 95 patients with serum HBV DNA lower than 3.0 log copies/mL at the time of nucleos(t)ide analog (NA) discontinuation.




Figure 4 Comparison of non-relapse rates using the Kaplan-Meier method between 10 patients with detectable hepatitis B e antigen (HBeAg) and 85 patients without detectable HBeAg at the time of nucleos(t)ide analog (NA) discontinuation.